Marti Aguilar-Coll

Dr. Marti Aguilar-Coll

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 November 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia
MAMarti Aguilar-Coll
Marti Aguilar-Coll
VVVanesa VICENS-ZYGMUNT
Vanesa VICENS-ZYGMUNT
JSJuan José Alegre Sancho
Juan José Alegre Sancho
GBGuadalupe Bermudo
Guadalupe Bermudo
MMMaría Molina-Molina
María Molina-Molina
Background/Objectives: Interstitial lung disease (ILD) is one of the most severe complications of rheumatoid arthritis (RA). Real-world data on antifibrotic treatment are needed. Our objective was to evaluate the real-world effectiveness and tolerability of antifibrotic agents in patients with progressive fibrosing RA-ILD. Methods: A longitudinal, retrospective, observational study was conducted on a cohort of RA-ILD patients treated with either nintedanib or pirfenidone. The data collected included pulmonary function test (PFT) results, adverse events (AEs), tolerability, and drug retention. Results: Twenty-seven patients were included; 25 (92.5%) initiated nintedanib, while two initiated pirfenidone. The median follow-up duration was 25 months (IQR 7–27). The mean decline in %pFVC and %pDLCO from ILD diagnosis to the initiation of antifibrotic therapy were −8.9% and −14.8%, respectively. After 6 months of treatment, most patients achieved stabilization in PFT: a ∆%pFVC of +1.2% (p = 0.611 compared with baseline) and a ∆%pDLCO of +3.9% (p = 0.400). Eighteen patients completed one year of therapy, with a modest improvement in %pFVC (+4.7%; p = 0.023) and stabilization in %pDLCO (−3.8%; p = 0.175). This trend persisted among the nine patients who completed 2 years of treatment (%pFVC +7.7%; p = 0.037 and %pDLCO −2.2%; p = 0.621). During the follow-up period, 15% of patients died, and 4% underwent lung transplantation. Adverse events occurred in 81% of patients, leading to discontinuation in 18.5% of cases. The most frequent adverse events were gastrointestinal events and hepatitis, leading to a permanent dose reduction of 40% for nintedanib and 14% for pirfenidone. A second antifibrotic agent was prescribed for 18.5% of the patients. At the end of the follow-up period, 63% of the total cohort remained on antifibrotic therapy. Conclusions: According to our results, antifibrotic initiation was associated with a modest improvement in the trajectory of %pFVC and stabilization in %pDLCO. The discontinuation rate in our cohort (37%) was higher than that reported in clinical trials but similar to that reported in previously published real-world studies.

1 May 2025 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
MAMarti Aguilar-Coll
Marti Aguilar-Coll
FGFrancisco Javier Narvaez Garcia
Francisco Javier Narvaez Garcia

31 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
DBDiego Benavent
Diego Benavent
PVPaola Vidal-Montal
Paola Vidal-Montal
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives: Sarcopenia is now recognized as a frequent and disabling accompaniment of rheumatoid arthritis (RA), although structured screening approaches are still rarely applied in everyday practice. The SARC-F questionnaire offers a simple, validated, patient-reported tool for sarcopenia screening, but its performance in RA remains largely unexplored. We aimed to evaluate the burden of sarcopenia risk, defined by abnormal SARC-F scores (≥4), and its clinical correlates in RA compared with age- and sex-matched controls. Methods: We conducted an observational case–control study including 275 RA patients (69.5% women) aged >50 years and 300 matched controls. Clinical, laboratory, and patient-reported outcomes were recorded. Sarcopenia risk was assessed using SARC-F (cutoff ≥ 4). RA patients also underwent grip strength and gait speed testing. Multivariable regression analyses were used to identify independent correlates of abnormal SARC-F results. Results: A SARC-F score ≥ 4 was observed in 26.9% of RA patients. Compared with controls, the burden was significantly higher in women with RA (34.0% vs. 24.7%, p < 0.05) but not in men (10.7% vs. 15.0%). Within the RA cohort, abnormal SARC-F was independently associated with female sex (OR 3.14, 95% CI 1.24–7.95) and higher RAPID3 scores (OR 1.25, 95% CI 1.18–1.33). More than half of RA patients exhibited low grip strength, with partial overlap with SARC-F findings. Conclusions: The SARC-F questionnaire revealed a notable burden of sarcopenia risk in RA, particularly among women. Combined with simple grip strength testing, it offers a feasible, low-cost approach to case finding, directly applicable in routine rheumatology practice. Incorporating this strategy may enhance recognition and management of sarcopenia in RA.

23 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
DBDiego Benavent
Diego Benavent
PVPaola Vidal-Montal
Paola Vidal-Montal
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives Nutritional risk is increasingly recognized as a relevant but under-assessed dimension of rheumatoid arthritis (RA), particularly in older adults managed in outpatient settings. Simple nutritional indices such as the Prognostic Nutritional Index (PNI) may help identify individuals at increased nutritional risk beyond conventional disease activity measures. This study aimed to characterize nutritional risk in older adults with RA using the Prognostic Nutritional Index, explore sex-specific patterns, and identify clinical associations of PNI variability, with complementary analyses focusing on high nutritional risk. Methods We conducted an observational cross-sectional study including 275 consecutive adults aged ≥50 years with RA attending routine follow-up at a tertiary rheumatology clinic. Nutritional risk was assessed using the PNI, calculated from serum albumin and total lymphocyte count, and analyzed primarily as a continuous variable and secondarily using established cut-off values. Clinical characteristics, inflammatory markers, body mass index, laboratory parameters, and patient-reported outcomes were recorded. Analyses were stratified by sex. Multivariable linear regression models were used to identify factors associated with PNI variability, and complementary logistic regression analyses were performed to explore factors independently associated with high nutritional risk (PNI < 40). Results More than half of the cohort (53.3%) exhibited PNI values compatible with nutritional risk. Men showed significantly lower PNI values than women, with a higher frequency of nutritional risk (61.5% vs. 49.7%, p < 0.01) and a markedly greater prevalence of high nutritional risk (18.0% vs. 5.0%, p < 0.001). Sex-specific association patterns were observed. In women, PNI showed only a weak inverse association with age. In contrast, in men, lower PNI values were associated with higher inflammatory burden, greater disease activity, lower body mass index, poorer mental health–related quality of life, and lower hemoglobin levels. In multivariable linear regression models restricted to men, hemoglobin emerged as the principal independent correlate of PNI. In complementary logistic regression analyses focusing on high nutritional risk (PNI < 40), hemoglobin remained the sole independent predictor (OR = 0.94, 95% CI 0.91–0.98; p < 0.01), supporting a robust association with clinically relevant nutritional risk. Conclusions Nutritional risk assessed by the PNI is common among older adults with RA and displays pronounced sex-specific patterns, with men showing a substantially higher burden of nutritional risk. The PNI captures a clinically relevant dimension of disease burden that extends beyond joint inflammation and traditional activity indices, supporting its use as a pragmatic nutritional screening tool in routine rheumatology practice.

19 February 2026 in Nutrients
Verified
Journal Article
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
DBDiego Benavent
Diego Benavent
PVPaola Vidal-Montal
Paola Vidal-Montal
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives: Nutritional risk is increasingly recognized as a relevant but under-assessed dimension of rheumatoid arthritis (RA), particularly in older adults managed in outpatient settings. Simple nutritional indices such as the Prognostic Nutritional Index (PNI) may help identify individuals at increased nutritional risk beyond conventional disease activity measures. This study aimed to characterize nutritional risk in older adults with RA using the Prognostic Nutritional Index, explore sex-specific patterns, and identify clinical associations of PNI variability, with complementary analyses focusing on high nutritional risk. Methods: We conducted an observational cross-sectional study including 275 consecutive adults aged ≥50 years with RA attending routine follow-up at a tertiary rheumatology clinic. Nutritional risk was assessed using the PNI, calculated from serum albumin and total lymphocyte count, and analyzed primarily as a continuous variable and secondarily using established cut-off values. Clinical characteristics, inflammatory markers, body mass index, laboratory parameters, and patient-reported outcomes were recorded. Analyses were stratified by sex. Multivariable linear regression models were used to identify factors associated with PNI variability, and complementary logistic regression analyses were performed to explore factors independently associated with high nutritional risk (PNI < 40). Results: More than half of the cohort (53.3%) exhibited PNI values compatible with nutritional risk. Men showed lower PNI values than women, with a markedly greater prevalence of high nutritional risk (18.0% vs. 5.0%, p < 0.001). In multivariable linear regression analyses, higher C-reactive protein levels and increasing age were independently associated with lower PNI values, whereas sex was not an independent determinant of PNI. In multivariable logistic regression analyses, increasing age and male sex were independently associated with high nutritional risk. In multivariable linear regression models restricted to men, hemoglobin emerged as the principal independent correlate of PNI. In complementary logistic regression analyses focusing on high nutritional risk (PNI < 40), hemoglobin remained the sole independent predictor (OR = 0.94, 95% CI 0.91–0.98; p < 0.01), supporting a robust association with clinically relevant nutritional risk. Conclusions: Nutritional risk assessed by the PNI is common among older adults with RA. Although sex does not independently determine PNI as a continuous measure, male sex is associated with severe nutritional risk. The PNI captures a clinically relevant dimension of disease burden that extends beyond joint inflammation and traditional activity indices, supporting its use as a pragmatic nutritional screening tool in routine rheumatology practice.

7 October 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
JNJoan M Nolla
Joan M Nolla
LVLidia Valencia-Muntalà
Lidia Valencia-Muntalà
LBLaura Berbel-Arcobé
Laura Berbel-Arcobé
DBDiego Benavent
Diego Benavent
PVPaola Vidal-Montal
Paola Vidal-Montal
CGCarmen Gómez-Vaquero
Carmen Gómez-Vaquero
Background/Objectives: Sarcopenia is increasingly recognized as a relevant comorbidity in rheumatoid arthritis (RA), yet systematic case finding is rarely implemented in clinical practice. The SARC-F questionnaire offers a simple, validated, patient-reported tool for sarcopenia screening, but its performance in RA remains largely unexplored. We aimed to evaluate the burden of sarcopenia risk, defined by abnormal SARC-F scores (≥4), and its clinical correlates in RA compared with age- and sex-matched controls. Methods: We conducted an observational case–control study including 275 RA patients (69.5% women) aged >50 years and 300 matched controls. Clinical, laboratory, and patient-reported outcomes were recorded. Sarcopenia risk was assessed using SARC-F (cutoff ≥4). RA patients also underwent grip strength and gait speed testing. Multivariable regression analyses were used to identify independent correlates of abnormal SARC-F results. Results: A SARC-F score ≥4 was observed in 28.8% of RA patients. Compared with controls, the burden was significantly higher in women with RA (34.0% vs. 24.7%, p < 0.05) but not in men (10.7% vs. 15.0%). Within the RA cohort, abnormal SARC-F was independently associated with female sex (OR 3.14, 95% CI 1.24–7.95) and higher RAPID3 scores (OR 1.25, 95% CI 1.18–1.33). More than half of RA patients exhibited low grip strength, with partial overlap with SARC-F findings. Conclusions: The SARC-F questionnaire revealed a notable burden of sarcopenia risk in RA, particularly among women. Combined with simple grip strength testing, it offers a feasible, low-cost approach to case finding, directly applicable in routine rheumatology practice. Incorporating this strategy may enhance recognition and management of sarcopenia in RA.